Mr. Friedland is co-founder (with Sheryl WuDunn) of FullSky Partners, an impact investment advisory firm focusing on return-on-mission (ROM) capital for enterprises with important solutions in areas that include education, the environment and domestic and global healthcare. Working with The 90/10 Institute and inspired by his counsel to Nobel Prize winner Dr. Luc Montagnier on the challenges of funding drug development for diseases that are ignored by Wall Street/VC investors, the FullSky Model™ utilizes Program Related Investments for at-scale ROM funding to enterprises with patient-centric Dx/Rx life science solutions. Mr. Friedland is also co-founder of ESGHealthMetrics which provides institutional asset owners (pension funds, endowments, etc.) and wealth managers with the gold-standard of trusted, conflict-free workforce health data as a material investment metric in the context of ESG assessments.
Mr. Friedland is a Root-Tilden Scholar, New York University School of Law, who began his legal career at Cravath, Swaine and Moore. As General Counsel to New York State’s Economic Development Agency, Mr. Friedland had the benefit of mentoring by Dr. George Low (President of RPI) and Dr. John Marberger, President of Stony Brook University and Presidential Science Advisor, on technology transfer of R&D from bench to bedside.